https://www.businesswire.com/news/home/20230303005382/en/Acadia-Pharmaceuticals-Announces-U.S.-FDA-Approval-of-DAYBUE%E2%84%A2-trofinetide-for-the-Treatment-of-Rett-Syndrome-in-Adult-and-Pediatric-Patients-Two-Years-of-Age-and-Older
0
0
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older - Business Wire
3/10/23 at 6:45pm
Organization
Business Wire
51 words
0
Comments
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE™ (trofinetide) for the
You are the first to view
Create an account or login to join the discussion